Ultrasound imaging technology developer Targeson has introduced Targestar-SA, an ultrasound contrast agent designed for use in preclinical drug discovery and basic science research.
Targestar-SA features echogenic lipid microbubbles bearing streptavidin on the shell surface. It can be used in ultrasound molecular imaging applications such as tumor angiogenesis, myocardial infarction, thrombosis, atherosclerosis, and other preclinical models of disease, according to the La Jolla, CA-based firm.
It can be used with most clinical and research ultrasound scanners; agent echogenicity is optimal at ultrasound frequencies in the 1-20 MHz range, Targeson said. Ultra-high-frequency imaging (20-40 MHz) is also possible.
Copyright © 2009 AuntMinnie.com
